

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

Phospho-Chk1 (Ser345) (133D3) Rabbit mAb

RRID:AB_331212

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2348, RRID:AB_331212

Antibody Information

URL: http://antibodyregistry.org/AB_331212

Proper Citation: Cell Signaling Technology Cat# 2348, RRID:AB_331212

Target Antigen: Chk1, phospho (Ser345)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IF-IC, F. Consolidation: AB_2080326, AB_10079109.

Antibody Name: Phospho-Chk1 (Ser345) (133D3) Rabbit mAb

Description: This monoclonal targets Chk1, phospho (Ser345)

Target Organism: monkey, rat, mouse, human

Clone ID: 133D3

Defining Citation: [PMID:28017544](#)

Antibody ID: AB_331212

Vendor: Cell Signaling Technology

Catalog Number: 2348

Alternative Catalog Numbers: 2348P, 2348S, 2348T, 2348L

Record Creation Time: 20250819T233908+0000

Record Last Update: 20250820T055958+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Chk1 (Ser345) (133D3) Rabbit mAb.

No alerts have been found for Phospho-Chk1 (Ser345) (133D3) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 190 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang Q, et al. (2026) FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity. *Molecular cell*.

Wang H, et al. (2026) Targeting the ER?? DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation. *Molecular cancer therapeutics*, 25(1), 107.

Guo J, et al. (2026) The cytotoxic effect of prexasertib is a consequence of dual inhibition on both CHK1 and AMPK. *Cell chemical biology*, 33(6), 767.

Koppenhafer SL, et al. (2026) DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. *Oncogene*, 45(28), 2823.

Zhou Z, et al. (2026) SUDS3 nuclear condensates decelerate DNA replication and safeguard genome stability. *Cell reports*, 45(7), 117713.

Aussel A, et al. (2026) Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas. *Nature communications*, 17(1).

Ialchina R, et al. (2026) Microenvironmental acidosis drives PARP- and ATM inhibitor resistance in p53 deficient pancreatic cancer. *iScience*, 29(3), 115112.

Planchard D, et al. (2026) Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. *Cancer cell*, 44(6), 1147.

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. *Cancer research*, 86(11), 2660.

Young TM, et al. (2026) CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. *Cancers*, 18(5).

Xu G, et al. (2026) Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer. *Cell reports*, 45(2), 116941.

Hurley K, et al. (2026) PARP1 recruits SPRTN to DNA-protein crosslinks through a conserved poly-ADP-ribose binding domain. *bioRxiv : the preprint server for biology*.

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. *Cell reports*, 45(1), 116784.

Spindler J, et al. (2026) SLX4IP limits replication stress globally and at ALT telomeres. *The EMBO journal*, 45(12), 4176.

Wang D, et al. (2026) PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors. *bioRxiv : the preprint server for biology*.

Planas-Paz L, et al. (2026) Targeting ATR signaling in sarcoma with homologous recombination deficiency. *Cancer letters*, 642, 218300.

Cui S, et al. (2026) Ski2-like helicase ASCC3 unwinds DNA upon fork stalling to control replication stress responses. *Cell reports*, 45(3), 117051.

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. *iScience*, 29(7), 116390.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Dutta Chowdhury D, et al. (2026) TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer. *Molecular cancer therapeutics*.